245
Participants
Start Date
May 31, 2005
Primary Completion Date
April 30, 2014
Study Completion Date
April 30, 2014
Erlotinib (tarceva)
Erlotinib 150mg orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events, death or completion of 3 years of therapy.
Placebo
Matched placebo orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events death or completion of 3 years of therapy.
Lincoln Hospital, The Bronx
Hematology Oncology Associates of Rockland, PC, New York
Queens Medical Associates, Fresh Meadows
Winthrop University Hospital, Mineola
Washington Cancer Institute, Washington D.C.
Frederick Smith, MD, Chevy Chase
Community Hematology Oncology, Olney
Sinai Hospital of Baltimore, Baltimore
Union Memorial Hospital, Baltimore
Harbor View Cancer Center, Baltimore
Franklin Square Hospital Center, Baltimore
Virginia Oncology Associates Research Program, Newport News
Morgantown Internal Medicine Group, Morgantown
Southeastern Medical Oncology Center, Goldsboro
SCOA-SC Onc Assoc, Columbia
Cancer Care of North Florida, Lake City
Mid Florida Oncology, Orange City
MD Anderson, Orlando
Oncology & Hematology Association of West Broward, Tamarac
Palm Beach Cancer Institute, West Palm Beach
Jupiter Medical Center, Jupiter
Florida Cancer Specialists, Fort Myers
Lee Cancer Clinic, Fort Myers
Pasco Hernando Oncology Associates, Brooksville
Pasco/Hernando Oncology, New Port Richey
Birmingham Hematology and Oncology Associates, LLC, Birmingham
Oncology Specialties, P.C., Huntsville
Kentucky Cancer Clinic, Hazard
Western Hematology Oncology, Paducah
The Cleveland Clinic Foundation Hematology/Med Oncology, Cleveland
Aultman Cancer Center, Canton
Investigative Clinical Research of Indiana LLC, Indianapolis
Howard Regional Health System, Kokomo
Bay Medical Cancer Center, Bay City
McFarland Clinic, Ames
Alexian Brothers Hospital Network, Elk Grove Village
Joliet Hematology Associates, Joliet
Methodist Cancer Center, Omaha
Southeast Nebraska Hematology/Oncology, Lincoln
Genesis Cancer Center, Hot Springs
Cooper Clinic, Fort Smith
Hope Oncology, Richardson
Blood and Cancer Center of East Texas, Tyler
Tyler Hematology/Oncology, Tyler
VA Department of Hematology/Oncology, Houston
Nevada Cancer Research Foundation, Las Vegas
Alta Bates Comprehensive Cancer Center, Berkeley
Mercy General Hospital, Sacramento
Northstate Cancer Speciality, Redding
Legacy Good Samaritan, Portland
Olympic Hematology/Oncology, Bremerton
St. Francis Hospital Cancer Center, Hartford
Connecticut Oncology Group, Middletown
George Bray Cancer Center/New Britain General Hospital, New Britain
Oncology and Hematology Associates, PC, New London
Whittingham Cancer Center at Norwalk Hospital, Norwalk
Hematology/Oncology PC/Carl and Dorothy Bennet Cancer Center, Stamford
Maine Center for Cancer Medicine, Scarborough
Lahey Clinic Medical Center, Burlington
Fallon Clinic Hematology/ Oncology, Worcester
Dartmouth-Hitchcock-Keene, Keene
Norris Cotton Cancer Center, Lebanon
The Center for Cancer and Hematologic Disease, Cherry Hill
Sussex County Medical Associates, Newton
Veterans Administration Medical Center, White River Junction
Collaborators (2)
Sanofi
INDUSTRY
Genentech, Inc.
INDUSTRY
Dartmouth-Hitchcock Medical Center
OTHER